| Literature DB >> 24156411 |
Syed Sikander Azam1, Sumra Wajid Abbasi.
Abstract
BACKGROUND: N-Acetylserotonin O-methyltransferase (ASMT) is an enzyme which by converting nor-melatonin to melatonin catalyzes the final reaction in melatonin biosynthesis in tryptophan metabolism pathway. High Expression of ASMT gene is evident in PPTs. The presence of abnormally high levels of ASMT in pineal gland could serve as an indication of the existence of pineal parenchymal tumors (PPTs) in the brain (J Neuropathol Exp Neurol 65: 675-684, 2006). Different levels of melatonin are used as a trait marker for prescribing the mood disorders e.g. Seasonal affective disorder, bipolar disorder, or major depressive disorder. In addition, melatonin levels can also be used to calculate the severity of a patient's illness at a given point in time.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24156411 PMCID: PMC3819668 DOI: 10.1186/1742-4682-10-63
Source DB: PubMed Journal: Theor Biol Med Model ISSN: 1742-4682 Impact factor: 2.432
Figure 1ASMT catalyzed melatonin synthesis.
Active site residues of ASMT
| TRP 11, 117, 285 | W |
| LYS 107, 223 | K |
| TYR 108 131, 336 | Y |
| GLY 110, 263 | G |
| SER 113 | S |
| CYS 116 | C |
| THR 112, 144, 207, 336 | T |
| LEU 142, 186, 308, 326 | L |
| GLU 152 | E |
| PHE 26,143, 156, 237 | F |
| ILE 277, 310 | I |
| ASP 238, 268, 284 | D |
| ARG 210, 280 | R |
| ASN 330 | N |
| VAL 333 | V |
| GLN 253, 334 | Q |
| MET331 | M |
Number of good, fair and poor ASMT docked complexes obtained by the different docking routines
| Gooda | 43 | 35 | 18 | 25 |
| Fairb | 18 | 28 | 13 | |
| Poorc | 12 | 16 | 22 | 15 |
agood on the bases of lowest binding affinities, RMSD < 2 Å and high docked scores.
bfair pose on the bases of lowest to moderate binding affinities, RMSD < 3 Å and >2 Å and moderate docking scores.
cpoor on the bases of high binding affinities, greater RMSD and lowest docked scores.
Figure 2Percentages of docked poses for ASMT docked complexes obtained by the different docking routines.
Time required for the docking of a single ligand
| AutoDock/Vina | 2-3 sec |
| GOLD | 1.66 sec |
| FlexX | 5 sec |
| FRED | 1.4 sec |
Figure 3Plot showing the correlation between the experimental bioactivities (PIC50) and a) binding affinities b) GOLD scores c) Chemgauss4 scores and d) binding energies.
Figure 4Docked conformation of ASMT with top ranked ligands showing the interaction with the crucial residues in the active site cleft using: (a) AutoDock/Vina (b) GOLD (c) FlexX (d) FRED.
Figure 5Docked poses: Binding mode of top ranked docked poses into ASMT binding cavity: (a) AutoDock/Vina (b) GOLD (c) FlexX (d) FRED For clarity, only interacting important residues are displayed in CPK style. The inhibitors were designed in licorice style, and part of the enzyme in the background was visualized in New Ribbon style using the VMD (Visual Molecular Dynamics) program.
Important interactions between the active residues of ASMT and Ligands within 5 Å
| ASMTB22 (AutoDock/Vina) | Arg280:HH11…O | 3.67 Å | Arg280:NH1…O | 3.78 Å | Leu160:CD2…C | 3.69 Å |
| Arg280:HH12…O | 3.29 Å | Tyr327:CE1…C | 3.40 Å | |||
| Arg280:HH12…O | 3.85 Å | Tyr108:CZ…C | 3.97 Å | |||
| Ser104:HG…N | 3.83 Å | Tyr108:CE2…C | 3.64 Å | |||
| Thr100:HG1…O | 2.23 Å | Tyr108:CE2…C | 3.77 Å | |||
| Thr100:HG1…O | 3.58 Å | Tyr108:CE2…C | 3.87 Å | |||
| Tyr108:HH…N | 3.56 Å | Tyr108:CD2…C | 3.92 Å | |||
| Tyr327: HH…O | 3.84 Å | Tyr108:CD2…C | 3.97 Å | |||
| Leu326:CD2…C | 3.49 Å | |||||
| Leu326:CB…C | 3.65 Å | |||||
| Leu326:CB…C | 3.78 Å | |||||
| Leu326:CG…C | 3.98 Å | |||||
| Leu326:CD2…C | 3.49 Å | |||||
| Leu326:C…C | 3.89 Å | |||||
| Trp117:CD1…C | 3.90 Å | |||||
| Trp117:CE2…C | 3.58 Å | |||||
| Trp117:CZ2…C | 3.96 Å | |||||
| Trp117:CD2…C | 3.62 Å | |||||
| Trp117:CD2…C | 3.94 Å | |||||
| Trp117:CG…C | 3.72 Å | |||||
| Trp117:CD2…C | 3.73 Å | |||||
| Phe26:CZ…C | 3.42 Å | |||||
| Phe:26:CE2…C | 3.81 Å | |||||
| GOLD | Arg280:HH12…O | 2.30 Å | Arg280:NH1…O | 2.91 Å | Tyr108: CE1…C | 3.45 Å |
| Arg280:HH11…O | 2.89 Å | Tyr108: CE1…C | 3.96 Å | |||
| Arg280:HH11…O | 3.91 Å | Tyr108:CE1…C | 3.92 Å | |||
| Asn330:H…N | 3.95Å | Tyr108: CZ…C | 3.43 Å | |||
| Ala159:O…H | 2.67Å | Tyr108: CD2…C | 3.86 Å | |||
| Tyr327:HH…O | 3.88 Å | Tyr108:CD2…C | 3.78 Å | |||
| Tyr108:HH…N | 3.90 Å | Tyr108:CE2…C | 3.77 Å | |||
| Tyr108:HH…N | 3.48 Å | Tyr108:CZ…C | 3.91 Å | |||
| Tyr108:OH…H | 3.71 Å | Tyr108:CZ…C | 3.79 Å | |||
| Ala159:O…H | 2.67Å | Tyr108:CD2…C | 3.87 Å | |||
| Tyr108:HH…N | 2.80 Å | Tyr327:CD1…C | 3.76 Å | |||
| Trp117:HE1…O | 3.89 Å | Tyr327:CD1…C | 3.74 Å | |||
| Tyr327:CD1…C | 3.58 Å | |||||
| Tyr327:CB…C | 3.82 Å | |||||
| Tyr366:CE2…C | 3.86 Å | |||||
| Tyr366:CE2…C | 3.89 Å | |||||
| Trp117:CG…C | 3.57 Å | |||||
| Trp117:CE2…C | 3.98 Å | |||||
| Trp117:CZ2…C | 3.51 Å | |||||
| Trp117:CH2…C | 3.48 Å | |||||
| Trp117:CB2…C | 3.98 Å | |||||
| Asn330:CB…C | 3.53 Å | |||||
| Leu326:C…C | 3.55 Å | |||||
| Leu326:CB…C | 3.99 Å | |||||
| FlexX | Arg210:H…O | 2.22Å | Arg210:N…O | 3.17Å | Thr195:CB…C | 3.07 Å |
| Arg210:H…N | 3.32Å | Arg210:NH1…O | 3.34 Å | Thr195:CG2…C | 3.54 Å | |
| Arg210:HH11…N | 3.29 Å | Lys223:NZ…O | 2.68 Å | Lys223:CE…C | 3.39 Å | |
| Arg210:HH12…O | 2.69 Å | Glu224:OE2…N | 2.96 Å | Lys223:CE…C | 3.99 Å | |
| Arg210:HH11…O | 3.26 Å | Glu224:OE1…N | 3.32 Å | Leu228:CD2…C | 3.14 Å | |
| Lys223:HZ3…O | 2.34 Å | Leu228:CD2…C | 3.51 Å | |||
| Lys223:HZ1…O | 2.51 Å | Leu228:CD1…C | 3.95 Å | |||
| Lys223:HZ2…O | 3.73 Å | Arg169:CG…C | 3.55 Å | |||
| Thr207:HG1…O | 1.65 Å | Arg169:CB…C | 3.83 Å | |||
| Thr207:HG1…O | 3.41 Å | His209:CD2…C | 2.63 Å | |||
| Val211:O…H | 1.67 Å | His209:CD2…C | 3.31 Å | |||
| Val211:N…H | 3.85 Å | His209:CD2…C | 3.39 Å | |||
| Phe212:N…H | 2.98Å | His209:CG…C | 3.50 Å | |||
| Glu224:OE2…H | 1.97 Å | His209:CG…C | 3.84 Å | |||
| Glu224:OE1…H | 2.54 Å | His209:CA…C | 3.35 Å | |||
| His209:CA…C | 3.92 Å | |||||
| S His209:CB…C | 3.93 Å | |||||
| Val211:CA…C | 3.49 Å | |||||
| Val211:CA…C | 3.51 Å | |||||
| Val211:C…C | 3.04Å | |||||
| Val211:C…C | 3.61Å | |||||
| Arg210:C…C | 3.94 Å | |||||
| Arg210:C…C | 3.96 Å | |||||
| Phe212:CB…C | 3.65 Å | |||||
| Phe212:CB…C | 3.62 Å | |||||
| Phe212:CD2…C | 3.66 Å | |||||
| Phe212:CD2…C | 3.38 Å | |||||
| Thr195:CG2…C | 3.54 Å | |||||
| Thr195:CB…C | 3.07 Å | |||||
| ASMT-A3 FRED | Tyr108:HH…N | 3.14 Å | Asn330:ND2…O | 3.25 Å | Tyr327:CD1…C | 3.88 Å |
| | Tyr108:HH…O | 3.37 Å | Lys107:NZ…O | 2.84 Å | Tyr327:CD1…C | 3.84 Å |
| Asn330:HD21…O | 3.75 Å | Tyr327:CD1…C | 3.61 Å | |||
| Asn330:HD22…O | 3.33 Å | Tyr327:CD1…C | 3.90 Å | |||
| Lys107:HZ3…O | 1.85 Å | Tyr327:CE1…C | 3.87 Å | |||
| Lys107:HZ2…N | 3.48 Å | Tyr327:CE1…C | 3.80 Å | |||
| Lys107:HZ3…N | 3.09 Å | Tyr327:CE1…C | 3.51 Å | |||
| Lys107:HZ2…O | 3.21 Å | Tyr327:CD1…C | 3.59 Å | |||
| Lys107:HZ1…O | 3.25 Å | Tyr327:CE1…C | 3.68 Å | |||
| Tyr327:HH…N | 3.90 Å | Tyr108:CZ…C | 3.93 Å | |||
| Tyr108:CE2…C | 3.35 Å | |||||
| Tyr108:CE2…C | 3.76 Å | |||||
| Tyr108:CE2…C | 3.90 Å | |||||
| Tyr108:CD2…C | 3.73 Å | |||||
| Tyr108:CZ…C | 3.86 Å | |||||
| Trp117:CE2…C | 3.69 Å | |||||
| Trp117:CZ2…C | 3.34 Å | |||||
| Trp117:CD1…C | 3.73 Å | |||||
| Trp117:CH2…C | 3.45 Å | |||||
Comparison: showing the PIC50 values, chemgauss scores, binding affinities, gold scores and binding energies
| 1 | 7.54 | 59.09 | -18.82 | |||
| 2 | 7e | 7.17 | -7.7 | 58.27 | -20.66 | |
| 3 | B20 | 7.17 | -7.7 | 58.31 | ||
| 4 | A7 | 7.21 | -4.3 | 55.01 | -20.91 | |
| 5 | A19 | 7.28 | -5 | 55.39 | ND | |
| 6 | 6e | 7.27 | -7.4 | 56.43 | -18.29 | |
| 7 | A2 | 7.21 | -4.3 | 54.47 | -21.03 | |
| 8 | 6b | 7.18 | -7.7 | -18.23 | ||
| 9 | B23 | 7.6 | -4.8 | 42.07 | ND | |
| 10 | 10f | 4.95 | -7.7 | 56 | -17.21 | |
| 11 | 7.17 | |||||
| 12 | A6 | 8.11 | -8.828648 | -7.7 | 53.85 | -17.84 |
| 13 | 6a | 7.85 | -8.7937 | -7.2 | 55.17 | -20.74 |
| 14 | A4 | 7.15 | -8.793257 | -7.5 | 39.34 | -11.62 |
| 15 | 7a | 7.08 | -8.77433 | -7.2 | 55.26 | -21.36 |
| 16 | 11 l | 4.92 | -8.765322 | -4.9 | 46.14 | |
| 17 | 11j | 4.17 | -8.731167 | -4.4 | 43.8 | -18.52 |
| 18 | 11o | 4.01 | -8.722329 | -4.4 | 40.92 | -15.44 |
| 19 | 11 h | 4.48 | -8.703998 | -4.7 | 44.39 | -17.31 |
| 20 | 21 | 8.73 | -8.70327 | 57.6 | -22 | |
| 21 | 10b | 4.63 | -8.558372 | -7.8 | 59.67 | |
| 22 | 11 k | 4.37 | -8.527354 | -4.5 | 40.02 | -18.04 |
| 23 | A16 | 7.43 | -8.509283 | -7.5 | 59.91 | -17.63 |
| 24 | A17 | 7.37 | -8.497904 | -7.2 | 47.57 | ND |
| 25 | A14 | 7.74 | -8.497536 | -7.1 | 51.87 | -16.17 |
| 26 | B27 | 7.85 | -8.416398 | -7.3 | 56.36 | -17.62 |
| 27 | 10a | 4.79 | -8.404483 | -7.4 | 56 | -17.51 |
| 28 | 11i | 4.28 | -8.376978 | -5.4 | 44.83 | -18.15 |
| 29 | B25 | 7.25 | -8.366087 | 58.6 | -21.6 | |
| 30 | 10e | 4.25 | -8.366087 | -21.8 | ||
| 31 | 11 t | 5.04 | -8.309559 | -4.5 | 40 | ND |
| 32 | 11p | 4.56 | -8.237691 | -5.8 | 39.37 | -11.19 |
| 33 | 18 | 7.83 | -8.195755 | -6.9 | 51.11 | -19.33 |
| 34 | 11f | 4.72 | -8.194806 | -4.7 | 44.48 | ND |
| 35 | dbc-amp | 5.67 | -8.177967 | -19.67 | ||
| 36 | 11r | 4.23 | -8.096362 | -4.5 | 48.35 | -15.37 |
| 37 | 11 g | 4.73 | -8.094617 | -4.8 | 44.78 | -18.91 |
| 38 | A5 | 7.55 | -8.016981 | -7.6 | 50.77 | -14.78 |
| 39 | 11n | 5.04 | -8.002397 | -5.1 | 53.35 | -11.13 |
| 40 | 11 m | NA | -8.002397 | -6.7 | 49.27 | -11.13 |
| 41 | 11b | 4.49 | -7.910209 | -5 | 41.77 | -18.51 |
| 42 | B28 | 7.8 | -7.861473 | -7.2 | 59.97 | |
| 43 | 11c | 4.06 | -7.86083 | -4.5 | 46.85 | -17.83 |
| 44 | 11q | 6.39 | -7.821584 | -4.7 | 48.09 | -16.1 |
| 45 | 17 | 7.91 | -7.810211 | -6.6 | -18.35 | |
| 46 | B24 | 7.96 | -7.760382 | -7.9 | -19.28 | |
| 47 | 8a | 4.92 | -7.682957 | -7.5 | 55.05 | -17.4 |
| 48 | 11 s | 4.98 | -7.644275 | -5.3 | 42.3 | -16.93 |
| 49 | A11 | 7.49 | -7.604273 | |||
| 50 | A15 | 7.68 | -7.576113 | -7.5 | -17.13 | |
| 51 | B26 | 7.19 | -7.290902 | -7.7 | 50.41 | -18.17 |
| 52 | A13 | 8.04 | -7.28357 | -5 | 60.21 | -14.29 |
| 53 | A1 | 7.36 | -6.714446 | -7 | 50.72 | -15.67 |
| 54 | 20b | 6.95 | ND | -18.29 | ||
| 55 | 20c | 8.09 | ND | -18.32 | ||
| 56 | Ramelotinine | 8.5 | ND | 45.36 | -16.17 | |
| 57 | 16 | 6.5 | ND | -7.8 | 60.81 | |
| 58 | 2a | 6 | ND | -9 | 56 | -19.08 |
| 59 | 4 | 7.06 | ND | -7.8 | 57 | -20.4 |
| 60 | 5-Methoxy | 3.82 | ND | -6.7 | 45.51 | -20.56 |
| 61 | 11 | 2.68 | ND | 51.08 | -16.31 | |
| 62 | 12c | 7.93 | ND | -7.8 | 55.42 | |
| 63 | 20a | 6 | ND | -7.9 | 59.03 | |
| 64 | A9 | 7.27 | ND | -4.3 | 43.31 | |
| 65 | A10 | 7.96 | ND | -4 | 54.87 | -19.04 |
| 66 | 19 | 5.12 | ND | -7.1 | 51.87 | -16.06 |
| 67 | 20 | 6.23 | ND | 57.53 | ||
| 68 | Melotinine | 6.79 | ND | -7.1 | 50.47 | -17.51 |
| 69 | N-Acetyl | 5.15 | ND | -7.2 | 44.88 | -19.38 |
| 70 | Agomalotinine | 8.67 | ND | -4.9 | 49.75 | -14.74 |
| 71 | SAM | 8.04 | ND | -6 | 45.21 | -17.46 |
| 72 | A8 | 7.85 | ND | -6.8 | 50.18 | -15.06 |
| 73 | A12 | 7.29 | ND | -7.1 | 37.66 | ND |
Highlighted ones are the best docking hits according to the corresponding affinities and scores.
ND: Not Docked.